Gene therapy for advanced lymphoma gets FDA approval

People with advanced lymphoma now have another type of treatment to consider. The Food and Drug Administration has approved Yescarta, a cell-based gene therapy designed to treat large B-cell lymphoma created by Kite Pharma. It's the second time the FDA has approved a gene therapy for use in the US following a procedure meant to treat leukemia earlier this year.

The therapy requires a patient's T-Cells, one type of white blood cells, to be harvested and modified. These engineered cells are designed to be attracted to a certain protein in tumor cells in order to kill them. Due to the complex nature of the procedure, a healthcare professional will have to go through training to be able to administer the pricey treatment -- The Wall Street Journal says it will cost patients around $373,000.Kite Pharma conducted a multicenter clinical trial involving 10...